-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PD-1 inhibitors have shown potential antitumor activity in non-small cell lung cancer (NSCLC.
This study included patients with stage IIB-IIIB, EGFR/ALK wild-type NSCLC with ECOG PS 0-1 statu.
A total of 53 eligible patients (median age: 62 years, IQR: 45-76; women: 5, 4%, squamous cell carcinoma: 42, 72%) receiving 2-4 cycles of neoadjuvant starting March 2021 treatmen.
46 cases (46/499,99%) of grade 1-2 tra.
Neoadjuvant therapy with toripril combined with platinum-doublet chemotherapy is a promising, tolerable and effective approach for the treatment of stage IIB-IIIB non-small cell lung cance.
Original source:
Abstract number: 2105
Neoadjuvant Toripalimab combination in patients with stage IIB-IIIB NSCLC: a single-arm, phase 2 trial (Renaissance Study)